174 related articles for article (PubMed ID: 36224724)
1. A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer.
Hidayat K; Zhou YY; Du HZ; Qin LQ; Shi BM; Li ZN
Pharmacoepidemiol Drug Saf; 2023 Feb; 32(2):107-125. PubMed ID: 36224724
[TBL] [Abstract][Full Text] [Related]
2. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
3. Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.
Igweokpala S; Sule NO; Douros A; Yu OHY; Filion KB
Diabetes Obes Metab; 2024 Feb; 26(2):721-731. PubMed ID: 38031234
[TBL] [Abstract][Full Text] [Related]
4. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
[TBL] [Abstract][Full Text] [Related]
6. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
7. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
8. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
9. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies.
Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S
Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423
[TBL] [Abstract][Full Text] [Related]
10. Incretin-mimetic therapies and pancreatic disease: a review of observational data.
Suarez EA; Koro CE; Christian JB; Spector AD; Araujo AB; Abraham S
Curr Med Res Opin; 2014 Dec; 30(12):2471-81. PubMed ID: 25180611
[TBL] [Abstract][Full Text] [Related]
11. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
12. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
Ryder RE
Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
[TBL] [Abstract][Full Text] [Related]
13. Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies.
Chai S; Liu F; Yu S; Yang Z; Sun F
J Diabetes Investig; 2023 Jul; 14(7):864-873. PubMed ID: 37147888
[TBL] [Abstract][Full Text] [Related]
14. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
15. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
[TBL] [Abstract][Full Text] [Related]
16. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
17. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Abd El Aziz M; Cahyadi O; Meier JJ; Schmidt WE; Nauck MA
Diabetes Obes Metab; 2020 Apr; 22(4):699-704. PubMed ID: 31750601
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.
Mannucci E; Monami M
Adv Ther; 2017 Jan; 34(1):1-40. PubMed ID: 27844335
[TBL] [Abstract][Full Text] [Related]
19. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
Liu J; Li L; Deng K; Xu C; Busse JW; Vandvik PO; Li S; Guyatt GH; Sun X
BMJ; 2017 Jun; 357():j2499. PubMed ID: 28596247
[No Abstract] [Full Text] [Related]
20. Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?
de Heer J; Göke B
Expert Opin Drug Saf; 2014 Nov; 13(11):1469-81. PubMed ID: 25270593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
